These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36688114)

  • 21. Factors associated with 12 months continuous heroin abstinence: findings from the Australian Treatment Outcome Study (ATOS).
    Darke S; Ross J; Teesson M; Ali R; Cooke R; Ritter A; Lynskey M
    J Subst Abuse Treat; 2005 Apr; 28(3):255-63. PubMed ID: 15857726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns of nonfatal heroin overdose over a 3-year period: findings from the Australian treatment outcome study.
    Darke S; Williamson A; Ross J; Mills KL; Havard A; Teesson M
    J Urban Health; 2007 Mar; 84(2):283-91. PubMed ID: 17265131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different Tokes for Different Folks: Use of Cannabis Products Among a Longitudinal Cohort of People with Heroin Dependence.
    Wilson J; Mills KL; Sunderland M; Freeman TP; Teesson M; Haber PS; Marel C
    Int J Ment Health Addict; 2023 May; ():1-17. PubMed ID: 37363767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns and Correlates of Sustained Heroin Abstinence: Findings From the 11-Year Follow-Up of the Australian Treatment Outcome Study.
    Darke S; Marel C; Slade T; Ross J; Mills KL; Teesson M
    J Stud Alcohol Drugs; 2015 Nov; 76(6):909-15. PubMed ID: 26562598
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Outcomes after detoxification for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS).
    Teesson M; Havard A; Ross J; Darke S
    Drug Alcohol Rev; 2006 May; 25(3):241-7. PubMed ID: 16753648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of major depression and drug-related problems amongst heroin users across 36 months.
    Darke S; Mills K; Teesson M; Ross J; Williamson A; Havard A
    Psychiatry Res; 2009 Mar; 166(1):7-14. PubMed ID: 19215987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-traumatic stress disorder among people with heroin dependence in the Australian treatment outcome study (ATOS): prevalence and correlates.
    Mills KL; Lynskey M; Teesson M; Ross J; Darke S
    Drug Alcohol Depend; 2005 Mar; 77(3):243-9. PubMed ID: 15734224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Australian Treatment Outcome Study (ATOS): what have we learnt about treatment for heroin dependence?
    Darke S; Ross J; Teesson M
    Drug Alcohol Rev; 2007 Jan; 26(1):49-54. PubMed ID: 17364836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rates and correlates of mortality amongst heroin users: findings from the Australian Treatment Outcome Study (ATOS), 2001-2009.
    Darke S; Mills KL; Ross J; Teesson M
    Drug Alcohol Depend; 2011 Jun; 115(3):190-5. PubMed ID: 21130585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns and costs of treatment for heroin dependence over 12 months: findings from the Australian Treatment Outcome Study.
    Shanahan M; Havard A; Teesson M; Mills K; Williamson A; Ross J
    Aust N Z J Public Health; 2006 Aug; 30(4):305-11. PubMed ID: 16956156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-injecting routes of administration among entrants to three treatment modalities for heroin dependence.
    Darke S; Hetherington K; Ross J; Lynskey M; Teesson M
    Drug Alcohol Rev; 2004 Jun; 23(2):177-83. PubMed ID: 15370024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Depression among heroin users: 12-Month outcomes from the Australian Treatment Outcome Study (ATOS).
    Havard A; Teesson M; Darke S; Ross J
    J Subst Abuse Treat; 2006 Jun; 30(4):355-62. PubMed ID: 16716851
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes and predictors of change in the physical health status of heroin users over 24 months.
    Williamson A; Darke S; Ross J; Teesson M
    Addiction; 2009 Mar; 104(3):465-70. PubMed ID: 19207357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modelling Long-Term Joint Trajectories of Heroin Use and Treatment Utilisation: Findings from the Australian Treatment Outcome Study.
    Marel C; Mills KL; Slade T; Darke S; Ross J; Teesson M
    EClinicalMedicine; 2019 Sep; 14():71-79. PubMed ID: 31709404
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Long-Term Relationship Between Cannabis and Heroin Use: An 18- to 20-year Follow-Up of the Australian Treatment Outcome Study (ATOS).
    Wilson J; Mills KL; Sunderland M; Freeman TP; Teesson M; Haber PS; Marel C
    Am J Psychiatry; 2024 Feb; 181(2):135-143. PubMed ID: 38018142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Attempted suicide among heroin users: 12-month outcomes from the Australian Treatment Outcome Study (ATOS).
    Darke S; Williamson A; Ross J; Teesson M
    Drug Alcohol Depend; 2005 May; 78(2):177-86. PubMed ID: 15845321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gender differences in physical and mental health outcomes among an aging cohort of individuals with a history of heroin dependence.
    Grella CE; Lovinger K
    Addict Behav; 2012 Mar; 37(3):306-12. PubMed ID: 22154506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Years of potential life lost amongst heroin users in the Australian Treatment Outcome Study cohort, 2001-2015.
    Darke S; Marel C; Mills KL; Ross J; Slade T; Tessson M
    Drug Alcohol Depend; 2016 May; 162():206-10. PubMed ID: 27021806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of baseline cocaine use on treatment outcomes for heroin dependence over 24 months: findings from the Australian Treatment Outcome Study.
    Williamson A; Darke S; Ross J; Teesson M
    J Subst Abuse Treat; 2007 Oct; 33(3):287-93. PubMed ID: 17889301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term patterns of treatment use for opioid use disorder (OUD): Findings from the 18-20-year Australian Treatment Outcome Study.
    Wilson J; Mills KL; Sunderland M; Freeman TP; Keaveny M; Haasnoot K; Teesson M; Haber PS; Marel C
    Int J Drug Policy; 2023 Oct; 120():104187. PubMed ID: 37713938
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.